• Upgrade for Higher Safety ▏AIM Rong’an Submitted Clinical Application for Serum-free Human Rabies Vaccine to CDE

    2021-12-30

    Rong’an Bio, a wholly-owned subsidiary of AIM Vaccine, has submitted its application of communication session for the freeze-dried rabies vaccine for human use (serum-free Vero cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. As an upgrade, the serum-free Vero cell human rabies vaccine is most prominently characterized by serum-free cell culture, which results in higher safety.

  • Hardcore Technology ▏AIM Convac Submitted Clinical Application for EV71-CA16 HFMD Vaccine (HDC) to CDE

    2021-12-09

    A few days ago, AIM Convac, a subsidiary of AIM Vaccine Co., Ltd, submitted its application of communication session for the EV71-CA16 bivalent HFMD vaccine (human diploid cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. This candidate vaccine can target the two most common pathogens causing the hand-foot-and-mouth disease, i.e., enteric virus type 71 (EV71) and Coxsackie virus group A type 16 (CA16), to play an immunoprotective role in the comprehensive control and prevention of an HFMD epidemic.

  • Upgrade for Higher Safety ▏AIM Rong’an Submitted Clinical Application for Serum-free Human Rabies Vaccine to CDE

    2021-12-30
    20211230192634_89294.jpg

    Rong’an Bio, a wholly-owned subsidiary of AIM Vaccine, has submitted its application of communication session for the freeze-dried rabies vaccine for human use (serum-free Vero cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. As an upgrade, the serum-free Vero cell human rabies vaccine is most prominently characterized by serum-free cell culture, which results in higher safety.

  • Hardcore Technology ▏AIM Convac Submitted Clinical Application for EV71-CA16 HFMD Vaccine (HDC) to CDE

    2021-12-09

    A few days ago, AIM Convac, a subsidiary of AIM Vaccine Co., Ltd, submitted its application of communication session for the EV71-CA16 bivalent HFMD vaccine (human diploid cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. This candidate vaccine can target the two most common pathogens causing the hand-foot-and-mouth disease, i.e., enteric virus type 71 (EV71) and Coxsackie virus group A type 16 (CA16), to play an immunoprotective role in the comprehensive control and prevention of an HFMD epidemic.

  • Rising Star of International First-line Vaccine ▏AIM Vaccine MCV4 Obtained Clinical Approval

    2021-12-01

    Another success of AIM Vaccine Co., Ltd.—its wholly-owned subsidiary AIM Vacin obtained the Notice of Approval for Drug Clinical Trial for its ACYW135 Meningococcus Conjugate Vaccine (MCV4) from the National Medical Products Administration on December 1, and will carry out clinical trials in accordance with the requirements in the Notice.MCV4 is an industry-recognized international first-line innovative vaccine, and so far no similar product of its kind has obtained approval in China.

  • R&D of vaccine targeted at COVID-19 Delta variant has been incorporated into “Pioneer Program” of Zhejiang Province for rolling submission to CDE.

    2021-11-27

    As declared by Zhejiang Provincial Department of Science and Technology on November 26, 2021, R&D of COVID-19 Vaccine Targeted at Delta Variant has been incorporated into Key “Pioneer” R&D Projects of Zhejiang Province for the year of 2022. This project is initiated by Ningbo Rong’an Biological Pharmaceutical Co., Ltd through cooperation with Zhejiang Provincial Center for Disease Control and Prevention. As the collaborator, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is accelerating the development of inactivated COVID-19 vaccine targeted at Delta variant. So far, it has entered the non-clinical animal evaluation stage, including animal safety evaluation, immunogenicity evaluation and protection evaluation. In the near future, it will proceed with rolling submission of relevant information to Center for Drug Evaluation (CDE), NMPA.

  • AIM MCV4 vaccine clinical application has been accepted for CDE approval, coming into the frontiers

    2021-11-27

    Clinical test application for ACW135 meningococcal polysaccharide vaccine (MCV4) as independently developed by AIM Vaccine has been accepted by Center for Drug Evaluation, NMPA for approval. This indicates the initiation of formal approval of MCV4 for clinical tests.

    Presently, there are only three foreign enterprises engaged in production of MCV4 worldwide, and no product has been approved for listing in China. AIM Vaccine comes into the frontier in China in terms of R&D of such key product.

  • 13v combined pneumococcal polysaccharide vaccine of AIM Vaccine has obtained phase-3 clinical ethical approval

    2021-10-15

    13v combined pneumococcal polysaccharide vaccine (PCV13) recognized as “King of Vaccines” worldwide accepted an important member in domestic front line prior to outbreak of COVID-19 epidemics. PCV13 as independently developed by AIM Vaccine Co., Ltd obtained phase-3 clinical ethical approval from Clinical Test Ethics Committee of Yunnan Provincial Center for Disease Control and Prevention on October 14. This indicates that such vaccine has entered the stage of phase-3 clinical test.

  • Phase-1 clinical test for mRNA COVID-19 vaccine of AIM Vaccine is in smooth progress, manifesting a high safety and tolerance

    2021-09-11

    By September 9, AIM Vaccine had completed low-dosage and medium-dosage recruitment of adult patients for mRNA COVID-19 vaccine at phase-1 clinical laboratory of Shulan (Hangzhou) Hospital. According to results of preliminary test, the vaccine has manifested a high safety and tolerance after inoculation.

  • AIM Vaccine enlisted for important contracted project for “Two-zone” construction in Beijing with introduced investments

    2021-09-04

    On the morning of September 3, Zhou Ting, Board Chairman and CEO of AIM Vaccine Co., Ltd attended “One-day for Beijing” and anniversary celebration of “Two-zone” construction at 2021 China International Fair for Trade in Services under invitation, and participated in the signing ceremony for “Two-zone” project. PRC head office and phase-1 project innovative vaccine industrialization base of AIM Vaccine have been listed as important contracted projects for “two-zone” construction in Beijing with introduced investments through strict screening. It is one of 37 key projects completed contract conclusion with Beijing Economic-Technological Development Area t the site on the current day.

  • AIM COVID-19 vaccine achieved critical progress in industrialization

    2021-07-21
    二次灭活水解罐

    Ningbo Rong’an Biological Pharmaceutical Co., Ltd, the wholly owned subsidiary of AIM Vaccine has recently obtained Approval Form of Clinical Trial as approved and issued by National Medical Products Administration.

1 2

Media Inquiry

Email to:mediacenter@aimbio.com